Filgotinib or lanraplenib in moderate to severe cutaneous lupus erythematosus: a phase 2, randomized, double-blind, placebo-controlled study
Victoria P Werth, Roy Fleischmann, Michael Robern, Zahi Touma, Iyabode Tiamiyu, Oksana Gurtovaya, Alena Pechonkina, Afsaneh Mozaffarian, Bryan Downie, Franziska Matzkies, Daniel Wallace, Victoria P Werth, Roy Fleischmann, Michael Robern, Zahi Touma, Iyabode Tiamiyu, Oksana Gurtovaya, Alena Pechonkina, Afsaneh Mozaffarian, Bryan Downie, Franziska Matzkies, Daniel Wallace
Abstract
Objectives: To explore the safety and efficacy of filgotinib (FIL), a Janus kinase 1 inhibitor, and lanraplenib (LANRA), a spleen kinase inhibitor, in cutaneous lupus erythematosus (CLE).
Methods: This was a phase 2, randomized, double-blind, placebo-controlled, exploratory, proof-of-concept study of LANRA (30 mg), FIL (200 mg) or placebo (PBO) once daily for 12 weeks in patients with active CLE. At week 12, PBO patients were rerandomized 1:1 to receive LANRA or FIL for up to 36 additional weeks.
Results: Of 47 randomized patients, 45 were treated (PBO, n = 9; LANRA, n = 19; FIL, n = 17). The primary endpoint [change from baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index Activity (CLASI-A) score at week 12] was not met. The least squares mean CLASI-A score change from baseline was -5.5 (s.e. 2.56) with PBO, -4.5 (1.91) with LANRA and -8.7 (1.85) with FIL. Numerical differences between FIL and PBO were greater in select subgroups. A ≥5-point improvement in the CLASI-A score at week 12 was achieved by 50.0%, 56.3% and 68.8% in the PBO, LANRA and FIL arms, respectively. A numerically greater proportion of patients in the FIL arm (50%) also achieved ≥50% improvement in the CLASI-A score at week 12 (37.5% PBO, 31.3% LANRA). Most adverse events (AEs) were mild or moderate in severity. Two serious AEs were reported with LANRA and one with FIL.
Conclusion: The primary endpoint was not met. Select subgroups displayed a numerically greater treatment response to FIL relative to PBO. LANRA and FIL were generally well tolerated.
Trial registration: ClinicalTrials.gov identifier NCT03134222.
Keywords: clinical trials and methods; cytokines and inflammatory mediators; inflammation; skin; systemic lupus erythematosus and autoimmunity.
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.
Figures
References
- Chen KL, Krain RL, Werth VP. Advancing understanding, diagnosis, and therapies for cutaneous lupus erythematosus within the broader context of systemic lupus erythematosus. F1000Res 2019;8:F1000 Faculty Rev-332.
- Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. Lupus Sci Med 2019;6:e000270.
- Kuhn A, Bijl M. Pathogenesis of cutaneous lupus erythematosus. Lupus 2008;17:389–93.
- Little AJ, Vesely MD. Cutaneous lupus erythematosus: current and future pathogenesis-directed therapies. Yale J Biol Med 2020;93:81–95.
- Borucki R, Werth VP. Expert perspective: an evidence-based approach to refractory cutaneous lupus erythematosus. Arthritis Rheum 2020;72:1777–85.
- Furie R, Khamashta M, Merrill JT et al. Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheum 2017;69:376–86.
- Furie RA, Morand EF, Bruce IN et al. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheum 2019;1:e208–19.
- Morand EF, Furie R, Tanaka Y et al. Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 2020;382:211–21.
- Furie R, Werth VP, Merola JF et al. Monoclonal antibody targeting BDCA2 ameliorates skin lesions in systemic lupus erythematosus. J Clin Invest 2019;129:1359–71.
- Werth V, Furie R, Romero-Diaz J et al. BIIB059, a humanized monoclonal antibody targeting BDCA2 on plasmacytoid dendritic cells (PDC), shows dose-related efficacy in the phase 2 LILAC study in patients (PTS) with active cutaneous lupus erythematosus (CLE). Ann Rheum Dis 2020;79:120–1.
- Alunno A, Padjen I, Fanouriakis A, Boumpas DT. Pathogenic and therapeutic relevance of JAK/STAT signaling in systemic lupus erythematosus: integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells 2019;8:898.
- Dey-Rao R, Smith JR, Chow S, Sinha AA. Differential gene expression analysis in CCLE lesions provides new insights regarding the genetics basis of skin vs. systemic disease. Genomics 2014;104:144–55.
- Taylor PC, Downie B, Elboudwarej E et al. Whole blood transcriptional changes following selective inhibition of Janus kinase 1 (JAK1) by filgotinib in adults with moderately-to-severely active rheumatoid arthritis with prior inadequate response to methotrexate (FINCH1). Ann Rheum Dis 2020;79:996–7.
- Taylor PC, Downie B, Elboudwarej E et al. Whole blood transcriptional changes following selective inhibition of Janus kinase 1 (JAK1) by filgotinib In MTX-naive adults with moderately-to-severely active rheumatoid arthritis (RA) (FINCH3). Ann Rheum Dis 2020;79:1017–8.
- Mócsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol 2010;10:387–402.
- Braegelmann C, Hölzel M, Ludbrook V et al. Spleen tyrosine kinase (SYK) is a potential target for the treatment of cutaneous lupus erythematosus patients. Exp Dermatol 2016;25:375–9.
- Blomgren P, Chandrasekhar J, Di Paolo JA et al. Discovery of lanraplenib (GS-9876): a once-daily spleen tyrosine kinase inhibitor for autoimmune diseases. ACS Med Chem Lett 2020;11:506–13.
- Askanase A, Byron M, Keyes-Elstein LL et al. Treatment of lupus nephritis with abatacept: the abatacept and cyclophosphamide combination efficacy and safety study. Arthritis Rheum 2014;66:3096–104.
- Furie R, Nicholls K, Cheng TT et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol 2014;66:379–89.
- Isenberg D, Furie R, Jones N et al. Efficacy, safety, and pharmacodynamic effects of the Bruton’s tyrosine kinase inhibitor, fenebrutinib (GDC-0853), in moderate to severe systemic lupus erythematosus: results of a phase 2 randomized controlled trial. Arthritis Rheumatol 2019;71(Suppl 10):abstract L15.
- Rovin BH, Furie R, Latinis K et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64:1215–26.
- Wallace DJ, Dörner T, Pisetsky D et al. Efficacy and safety of evobrutinib (M2951) in adult patients with systemic lupus erythematosus who received standard of care therapy: a phase ii, randomized, double-blind, placebo-controlled dose ranging study. Arthritis Rheumatol 2020;72(Suppl 10):abstract 0865.
- Merrill JT, Manzi S, Aranow C et al. Lupus community panel proposals for optimising clinical trials: 2018. Lupus Sci Med 2018;5:e000258.
- Chang AY, Ghazi E, Okawa J, Werth VP. Quality of life differences between responders and nonresponders in the treatment of cutaneous lupus erythematosus. JAMA Dermatol 2013;149:104–6.
- Klein R, Moghadam-Kia S, LoMonico J et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus. Arch Dermatol 2011;147:203–8.
- Chakka S, Krain RL, Ahmed S et al. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol 2021;84:1562–7.
- Werth V, Karnell JL, Rees W et al. Targeting plasmacytoid dendritic cells improves cutaneous lupus erythematosus skin lesions and reduces type I interferon levels: results of a phase 1 study of VIB7734. Arthritis Rheumatol 2020;72(Suppl 10):abstract L10.
- Merrill JW, Worth V, Furie R et al. Efficacy and safety of iberdomide in patients with active systemic lupus erythematosus: 24-week results of a phase 2, randomized, placebo-controlled study. Arthritis Rheumatol 2020;72(Suppl 10):abstract 0987.
- Furie R, van Vollenhoven R, Kalunian K et al. Efficacy and safety results from a phase 2, randomized, double-blind trial of BIIB059, an anti-BDCA2 antibody, in SLE. Arthritis Rheumatol 2020;72(Suppl 10):abstract 0935.
- Werth V, Furie R, Morand E et al. Early and sustained reduction in severity of skin disease with anifrolumab treatment in patients with active SLE measured by the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI): pooled data from 2 phase 3 studies. Arthritis Rheumatol 2020;72(Suppl 10):abstract 0985.
- Albrecht J, Taylor L, Berlin JA et al. The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus. J Invest Dermatol 2005;125:889–94.
- van Vollenhoven RF, Petri MA, Cervera R et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012;71:1343–9.
- Coricello A, Mesiti F, Lupia A, Maruca A, Alcaro S. Inside perspective of the synthetic and computational toolbox of JAK inhibitors: recent updates. Molecules 2020;25: 3321.
- Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res 2020;13:519–31.
- Mease P, Coates LC, Helliwell PS et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:2367–77.
- Szilveszter KP, Németh T, Mócsai A. Tyrosine kinases in autoimmune and inflammatory skin diseases. Front Immunol 2019;10:1862.
- van der Heijde D, Baraliakos X, Gensler LS et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:2378–87.
- Vermeire S, Schreiber S, Petryka R et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017;389:266–75.
- Xeljanz (tofacitinib) prescribing information. (11 December, date last accessed).
- Wallace DJ, Furie RA, Tanaka Y et al. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 2018;392:222–31.
- Pamuk ON, Tsokos GC. Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases. Arthritis Res Ther 2010;12:222.
- Uzé G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol 2007;316:71–95.
- Sarkar MK, Hile GA, Tsoi LC et al. Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa. Ann Rheum Dis 2018;77:1653–64.
- Tsoi LC, Hile GA, Berthier CC et al. Hypersensitive IFN responses in lupus keratinocytes reveal key mechanistic determinants in cutaneous lupus. J Immunol 2019;202:2121–30.
- Hinojosa-Azaola A, Romero-Diaz J, Vargas-Ruiz AG et al. Venous and arterial thrombotic events in systemic lupus erythematosus. J Rheum 2016;43:576–86.
- Tavilisse (fostamatinib disodium hexahydrate) prescribing information. (11 December, date last accessed).
- Genovese MC, Kalunian K, Gottenberg JE et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA 2019;322:315–25.
Source: PubMed